PMC:7441788 / 8214-8487 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T35","span":{"begin":215,"end":222},"obj":"Body_part"}],"attributes":[{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T67","span":{"begin":204,"end":208},"obj":"Disease"}],"attributes":[{"id":"A67","pred":"mondo_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T87","span":{"begin":37,"end":45},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T92","span":{"begin":49,"end":51},"obj":"Chemical"},{"id":"T93","span":{"begin":215,"end":222},"obj":"Chemical"}],"attributes":[{"id":"A92","pred":"chebi_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A93","pred":"chebi_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T65","span":{"begin":49,"end":51},"obj":"Chemical"},{"id":"T66","span":{"begin":215,"end":222},"obj":"Chemical"}],"attributes":[{"id":"A65","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T71","span":{"begin":204,"end":208},"obj":"Species"}],"attributes":[{"id":"A71","pred":"ncbi_taxonomy_id","subj":"T71","obj":"NCBItxid:694009"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T67","span":{"begin":0,"end":273},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"355","span":{"begin":134,"end":138},"obj":"Gene"},{"id":"356","span":{"begin":195,"end":199},"obj":"Gene"},{"id":"361","span":{"begin":204,"end":212},"obj":"Species"},{"id":"363","span":{"begin":33,"end":36},"obj":"Species"},{"id":"367","span":{"begin":49,"end":51},"obj":"Chemical"},{"id":"368","span":{"begin":52,"end":55},"obj":"Chemical"}],"attributes":[{"id":"A355","pred":"pubann:denotes","subj":"355","obj":"Gene:59272"},{"id":"A356","pred":"pubann:denotes","subj":"356","obj":"Gene:59272"},{"id":"A361","pred":"pubann:denotes","subj":"361","obj":"Tax:694009"},{"id":"A363","pred":"pubann:denotes","subj":"363","obj":"Tax:11118"},{"id":"A367","pred":"pubann:denotes","subj":"367","obj":"MESH:D002738"},{"id":"A368","pred":"pubann:denotes","subj":"368","obj":"MESH:D006886"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T86","span":{"begin":134,"end":138},"obj":"Protein"},{"id":"T87","span":{"begin":195,"end":199},"obj":"Protein"},{"id":"T88","span":{"begin":213,"end":222},"obj":"Protein"}],"attributes":[{"id":"A86","pred":"uniprot_id","subj":"T86","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A87","pred":"uniprot_id","subj":"T87","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A88","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9UIP0"},{"id":"A89","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9UIN9"},{"id":"A90","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9UIN8"},{"id":"A91","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9UIN7"},{"id":"A92","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9UIN6"},{"id":"A93","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9UBH8"},{"id":"A94","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NRH8"},{"id":"A95","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NRH7"},{"id":"A96","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NRH6"},{"id":"A97","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NRH5"},{"id":"A98","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NRH4"},{"id":"A99","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NPG5"},{"id":"A100","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NPE0"},{"id":"A101","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q9NP52"},{"id":"A102","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q95IF9"},{"id":"A103","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q8N5P3"},{"id":"A104","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q8IZU6"},{"id":"A105","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q8IZU5"},{"id":"A106","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q8IZU4"},{"id":"A107","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q86Z04"},{"id":"A108","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q7YR44"},{"id":"A109","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q7LA71"},{"id":"A110","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q7LA70"},{"id":"A111","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q5STD2"},{"id":"A112","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q5SQ85"},{"id":"A113","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q1XI16"},{"id":"A114","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q1XI12"},{"id":"A115","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/Q15517"},{"id":"A116","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/O43509"},{"id":"A117","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/O19084"},{"id":"A118","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/B0UYZ7"},{"id":"A119","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/B0S7V2"},{"id":"A120","pred":"uniprot_id","subj":"T88","obj":"https://www.uniprot.org/uniprot/A5A6L9"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T35","span":{"begin":215,"end":222},"obj":"Body_part"}],"attributes":[{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T8","span":{"begin":108,"end":130},"obj":"http://purl.obolibrary.org/obo/GO_0033578"},{"id":"T9","span":{"begin":117,"end":130},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T60","span":{"begin":204,"end":208},"obj":"Disease"}],"attributes":[{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T8","span":{"begin":108,"end":130},"obj":"http://purl.obolibrary.org/obo/GO_0033578"},{"id":"T9","span":{"begin":117,"end":130},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T8","span":{"begin":108,"end":130},"obj":"http://purl.obolibrary.org/obo/GO_0033578"},{"id":"T9","span":{"begin":117,"end":130},"obj":"http://purl.obolibrary.org/obo/GO_0070085"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"355","span":{"begin":134,"end":138},"obj":"Gene"},{"id":"356","span":{"begin":195,"end":199},"obj":"Gene"},{"id":"361","span":{"begin":204,"end":212},"obj":"Species"},{"id":"363","span":{"begin":33,"end":36},"obj":"Species"},{"id":"367","span":{"begin":49,"end":51},"obj":"Chemical"},{"id":"368","span":{"begin":52,"end":55},"obj":"Chemical"}],"attributes":[{"id":"A355","pred":"tao:has_database_id","subj":"355","obj":"Gene:59272"},{"id":"A356","pred":"tao:has_database_id","subj":"356","obj":"Gene:59272"},{"id":"A361","pred":"tao:has_database_id","subj":"361","obj":"Tax:694009"},{"id":"A363","pred":"tao:has_database_id","subj":"363","obj":"Tax:11118"},{"id":"A367","pred":"tao:has_database_id","subj":"367","obj":"MESH:D002738"},{"id":"A368","pred":"tao:has_database_id","subj":"368","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T67","span":{"begin":0,"end":273},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therefore, the mechanism of anti-CoV activity of CQ/HCQ may be at least partly related to the impairment of terminal glycosylation of ACE2, which may result in reduced binding affinities between ACE2 and SARS CoV S protein, thereby blocking receptor recognition (Figure 1)."}